Scarica l'app Stockscreener
3.41
2.10%
0.07
Precedente Chiudi:
$3.34
Aprire:
$3.48
Volume 24 ore:
4,057
Relative Volume:
0.11
Capitalizzazione di mercato:
$100.41M
Reddito:
-
Utile/perdita netta:
$-1.77M
Rapporto P/E:
-25.76
EPS:
-0.1324
Flusso di cassa netto:
$-1.46M
1 W Prestazione:
-2.01%
1M Prestazione:
-2.01%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.41
$3.48
Intervallo di 1 settimana:
$3.20
$3.48
Portata 52W:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Nome
Turn Therapeutics Inc
Settore
Industria
Telefono
(818) 564-4011
Indirizzo
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.41 | 100.41M | 0 | -1.77M | -1.46M | -0.1324 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-29 | Iniziato | D. Boral Capital | Buy |
Turn Therapeutics Inc Borsa (TTRX) Ultime notizie
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat
TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Analyst Insights | TTRX Stock News - GuruFocus
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - pharmiweb.com
Turn Therapeutics Secures Growth Capital to Advance Dermatology - TipRanks
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - marketscreener.com
Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka
Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX - MarketBeat
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga España
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - MarketBeat
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView
Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
TTRX Should I Buy - Intellectia AI
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Will Ovid Therapeutics Inc. announce a stock splitQuarterly Market Review & Detailed Earnings Play Strategies - mfd.ru
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
Will Turn Therapeutics Turn The Corner In 2026? - RTTNews
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Yahoo Finance
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
TTRX Forecast — Price Prediction for 2026. Should I Buy TTRX? - Intellectia AI
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors - TipRanks
Reviewing Turn Therapeutics (TTRX) and Its Peers - Defense World
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Turn Therapeutics (TTRX) vs. Its Peers Head to Head Survey - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
Financial Review: Turn Therapeutics (TTRX) & Its Peers - Defense World
Turn Therapeutics Inc Azioni (TTRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):